NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Natalia Elliot | January 29, 2025 | News story | Sales and Marketing | Duchenne Muscular Dystrophy, EC, EMA, FDA, Santhera Pharmaceuticals, positive
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence (NICE) for AGAMREE (vamorolone) to be used as treatment of Duchenne Muscular Dystrophy (DMD) in patients who are aged 4 or older in the UK.
The guidance follows the approval of vamorolone from the Medicines and products Regulatory Agency (MHRA) in January earlier this year. AGAMREE is currently the only fully approved treatment for DMD in the UK, EU and US. Approval from the European Medicines Agency (EMA) was given in late 2023, following on from the approval from the US Food and Medicines Agency (FDA). EMA approval was based on the results of a clinical trial, VISION-DMD, which demonstrated a reduction in adverse events related to bone growth in comparison to prednisolone, another type of corticosteroid.
At the time of the FDA approval, CEO of Santhera Dario Eklund stated: “We are delighted to secure FDA approval which comes just weeks after the positive opinion from the CHMP of the European Medicines Agency. This is a hugely important moment for DMD patients who need an efficacious and well-tolerated therapy for this debilitating condition.”
Duchenne Muscular Dystrophy is an orphan disease which primarily affects young boys due to the way it is inherited. Children affected by the disease may have difficulty walking, sitting, running, speaking, and developing due to muscle weakness.
Natalia Elliot
29/1/25
Related Content
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
MedPharm announces US FDA inspection of North Carolina manufacturing facility
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
